TAGRISSO® (osimertinib) | AURA3 Study
Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis - Hirashima - 2019 - Cancer Science - Wiley Online Library
Stream Annals of Oncology - Prof. Tony Mok discusses the overall survival analysis of the AURA3 trial by ESMO Podcasts | Listen online for free on SoundCloud
TAGRISSO® (osimertinib) | AURA3 Study
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. - Abstract - Europe PMC
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
TAGRISSO® (osimertinib) | FLAURA
d.planchard on Twitter: "Important result awaiting in EGFR mut pts :OS of AURA3 trial : just confirm to use osimertinib first line @myESMO #esmoasia19 https://t.co/Dwh04T0C4N" / Twitter
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
Asia Pacific Biotech News
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - ScienceDirect
Real-World Data Of Osimertinib In Patients With Pretreated Non-Small C | CMAR
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
TAGRISSO® (osimertinib) | AURA3 Study
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study | Future Oncology
TAGRISSO® (osimertinib) | AURA3 Study
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer | NEJM
AURA3 Clinical Study Data – TAGRISSO® (osimertinib)
